Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

BMT302
Phase II Ibrutinib Maintenance After Reduced-intensity Conditioning & Allogeneic HCT in Acute Leukemia
PI: Rezvani Stanford

FLT3 Mutation

BMT322
Phase III FLT3 Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML
PI: Muffy BMT CTN

Advanced Disease

Matched Related Donor

BMT236
Phase II/III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH
PI: Meyer NIH

KEY

Pending
Open for Enrollment
Observational Study

Link
Trial Posting

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu